We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Mast Cell Biomarker Predicts Severity of Dengue

By LabMedica International staff writers
Posted on 13 May 2013
Print article
Image: Human mast cells (Photo courtesy of Madeleine Rådinger).
Image: Human mast cells (Photo courtesy of Madeleine Rådinger).
A protein produced by mast cells in the immune system may predict which people infected with dengue virus will develop life-threatening complications.

Dengue virus (DENV) spread by mosquitoes, infects as many as 390 million people worldwide each year, and is a significant health issue in tropical areas of the world including parts of Latin America and Asia, and health professionals in Florida have reported cases in recent years.

Scientists at Duke University (Durham, NC, USA) working with their colleagues at Duke-National University of Singapore investigated the role of mast cells in attacking dengue virus in humans, and identified a biomarker derived from the mast cells, that appeared to predict the most severe cases of the disease in human patients.

Samples used for the investigation were derived from patients that ranged in age from 18 to 77 years, with a mean of 40 years; 42% of samples were obtained from females, and 58% from males. Dengue positive samples were determined based on physician diagnosis as well as molecular tests including reverse transcriptase polymerase chain reaction (RT-PCR) for viral ribonucleic acid (RNA).

The dengue fever (DF) and dengue hemorrhagic fever (DHF) patient sera used in this study were previously determined to be positive for serotypes 1, 2, or 3 by RT-PCR using the OneStep RT-PCR Kit (Qiagen; Valencia, CA, USA). Enzyme-linked immunosorbent assay (ELISA) kits for the human mast cell biomarker chymase, a serine protease, were obtained from Antibodies-Online (Atlanta, GA, USA).

Patients that were diagnosed with DF or DHF showed chymase levels in serum obtained during the acute phase of infection were significantly higher than levels in the serum of either healthy controls or individuals with fever that were DENV negative by RT-PCR. DF patients displayed an increase in serum chymase that was approximately 10 times higher than in healthy individuals or DENV-negative patients while, in DHF patients, chymase levels 30 times higher than healthy controls were detected.

Soman N. Abraham, PhD, a professor at Duke University and the senior author of the study, said,” In addition to revealing a potential new way to diagnose and treat dengue infections, these finding may have much broader applicability for other infectious diseases where vascular leakage is a major pathologic outcome.” The study was published on April 30, 2013, in the journal eLife.

Related Links:
Duke University
Duke-National University of Singapore
Antibodies-Online


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.